Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITALITY-HFpEF: Vericiguat in heart failure with preserved ejection fraction
2018-000298-65Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vericiguat in heart failure with preserved ejection fraction (HFpEF) and chronic heart failure (CHF) (3 arms), sponsored by Bayer. Primary endpoint: Change in KCCQ PLS from baseline to week 24. Started Apr 2018; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2018-000298-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000298-65.